Exhibit 99.1 Camping World Holdings, Inc. Reports Fourth Quarter 2025 Results LINCOLNSHIRE, IL – February 24, 2026 (BUSINESS WIRE) -- Camping World Holdings, Inc. (NYSE: CWH) ("CWH" or, collectively with its subsidiaries, the "Company" or "Camping World"), America's Largest Recreational Vehicle Dealer, today reported results for the fourth quarter and full year ended December 31, 2025. Matthew Wagner, Chief Executive Officer and President of CWH stated, "2025 was a pivotal year for our organization. We retu ...

Patient and Product Information - Jazz Pharmaceuticals reported approximately 16,175 patients taking Xywav by the end of 2025, including about 10,950 with narcolepsy and 5,225 with idiopathic hypersomnia (IH) [445]. - Xywav has demonstrated a 92% reduction in sodium content compared to Xyrem, making it a safer option for patients with narcolepsy and IH [442]. - The company achieved benefit coverage for Xywav in both narcolepsy and IH for approximately 90% of commercial lives in the U.S. [444]. - Epidiolex, acquired in May 2021, is approved for treating seizures associated with LGS, DS, and TSC, and is now launched and reimbursed in over 40 countries [446]. - Ziihera received accelerated approval from the FDA in November 2024 for treating adults with previously treated, unresectable or metastatic HER2-positive BTC [448]. - The FDA recognized seven years of orphan drug exclusivity (ODE) for Xywav in narcolepsy through January 2028 [442]. - The company focuses on rare diseases, which often have high unmet needs and small patient populations, allowing for efficient commercialization [435]. - Jazz Pharmaceuticals aims to leverage its scalable operating model to effectively reach patients globally [435]. Research and Development - The company continues to invest in R&D programs that align with its rare disease strategy [436]. - JZP898, a differentiated immuno-oncology molecule, entered Phase 1 trials after a $15 million upfront payment to Werewolf, with potential milestone payments up to $1.26 billion [463]. - JZP053, a preclinical epilepsy treatment, was licensed from Saniona for $42.5 million upfront, with potential milestone payments up to $800 million [465]. - The company initiated a Phase 1b trial for Epidiolex to evaluate its effectiveness in reducing focal seizures, with ongoing trials for multiple product candidates including zanidatamab and Vyxeos [466]. - Zanidatamab's Phase 3 HERIZON-GEA-01 trial showed statistically significant progression-free survival and overall survival benefits in HER2-positive locally advanced or metastatic GEA [470]. - The company has ongoing trials for multiple oncology products, including Rylaze, Zepzelca, Ziihera, Modeyso, Vyxeos, and Defitelio, which are critical for its growth strategy [476]. - The company’s growth strategy includes continued investment in R&D activities, with potential risks if clinical development does not succeed or regulatory approvals are delayed [477]. Financial Performance - Product sales for 2025 reached $4,021,849, a 5% increase from 2024's $3,821,164 [485]. - Xywav product sales increased by 12% in 2025, driven by a 14% increase in sales volumes, with 10,950 patients using it for narcolepsy and 5,225 for idiopathic hypersomnia (IH) by the end of 2025 [490]. - Xyrem product sales decreased by 38% in 2025, primarily due to a 33% drop in sales volumes attributed to competition from high-sodium oxybate [488]. - Epidiolex/Epidyolex product sales increased by 9% in 2025, mainly due to a 7% increase in sales volumes driven by higher demand [490]. - Total revenues for 2025 were $4,267,586, reflecting a 5% increase from $4,068,950 in 2024 [488]. - Selling, general and administrative expenses rose by 31% in 2025 to $1,809,271, compared to $1,385,294 in 2024 [485]. - Research and development expenses decreased by 11% in 2025 to $782,736, down from $884,000 in 2024 [485]. - Interest expense decreased by 18% in 2025 to $195,051, compared to $238,097 in 2024 [485]. - The company anticipates potential adverse effects on margins due to increased tariffs on imported pharmaceutical products starting as early as fiscal 2026 [483]. - The IRA mandates price negotiations for certain high Medicare spend drugs starting in 2026, which could limit commercial opportunities and negatively impact revenues [479]. Product Sales and Market Dynamics - Defitelio/defibrotide product sales decreased by 8% in 2025 compared to 2024, while Vyxeos product sales decreased by 10% in the same period, both primarily due to decreased sales volumes [493][496]. - Modeyso product sales were $48.0 million in 2025 following its launch in August 2025, and Ziihera product sales were $24.8 million in 2025 after its launch in December 2024 [493]. - Total revenues in 2026 are expected to increase compared to 2025, driven by growth in rare oncology and epilepsy products, offset by a reduction in oxybate revenues [495]. - Cost of product sales increased in 2025 compared to 2024, with a gross margin of 87.5% in 2025, down from 88.3% in 2024 [496]. - Selling, general and administrative expenses increased by $233.5 million due to Xyrem antitrust litigation settlements in 2025 [498]. - R&D expenses decreased by $101.3 million in 2025 compared to 2024, totaling $782.7 million, primarily due to lower costs related to clinical trials [501]. - The company faces competition from generic versions of high-sodium oxybate, with Amneal and Hikma launching their AG products, which could negatively impact Xywav and Xyrem sales [469][472]. - The commercial success of Epidiolex/Epidyolex is uncertain, with potential competition from generic products and non-FDA approved CBD preparations [475]. Acquisitions and Strategic Moves - Chimerix Acquisition completed for $944.2 million, adding Modeyso to the oncology portfolio, which received FDA accelerated approval in August 2025 for treating H3 K27M mutation glioma [449]. - The company received FDA approval for Modeyso in August 2025 for treating diffuse midline glioma with H3 K27M mutation, following the acquisition of Chimerix [470]. - The company has entered into agreements with major PBMs in the U.S. to support the commercialization of Xywav [444]. - The New Repurchase Program authorized by the board allows for the repurchase of ordinary shares up to $500.0 million, replacing the previous program of $1.5 billion [512]. - In 2024, the company repurchased 2.8 million ordinary shares for a total of $311.4 million, with an average purchase price of $110.06 per share [512]. Cash Flow and Debt Management - Net cash provided by operating activities decreased by $40.1 million in 2025 to $1,355.8 million, primarily due to $323.5 million in litigation settlement expenses [515]. - Net cash used in investing activities increased by $1.0 billion in 2025 compared to 2024, driven by significant acquisitions and investments [517]. - The company reported a net cash outflow of $873.4 million from financing activities in 2025, a decrease of $893.9 million compared to 2024 [514]. - The Chimerix Acquisition resulted in an outflow of $858.1 million in 2025, contributing to the increase in investing activities [518]. - As of December 31, 2025, the company had cash, cash equivalents, and investments of $2.4 billion, with a long-term debt principal balance of $5.4 billion [507]. - The interest rate on the Tranche B-2 Dollar Term Loans was 5.97% as of December 31, 2025, with an effective interest rate of 8.32% [523]. - The company issued $1.0 billion principal amount of 2030 Notes in September 2024, with an interest rate of 3.125% per year [532]. - The Amended Revolving Credit Facility was increased from $500.0 million to $885.0 million in November 2024, extending the maturity date [524]. Tax and Valuation - The income tax benefit was $272.4 million in 2025, primarily due to the reversal of a valuation allowance against certain deferred tax assets [506]. - The company maintains a valuation allowance against certain deferred tax assets where realizability is not certain, evaluating the likelihood of realization periodically [570]. - The company did not recognize an impairment charge related to intangible assets in 2025, 2024, or 2023, indicating stable asset valuations [566]. - As of December 31, 2025, the company had $1.8 billion of goodwill resulting from acquisitions accounted for as business combinations, with no impairment recognized during 2025, 2024, or 2023 [559][566]. - The company reported $4.4 billion of finite-lived intangible assets as of December 31, 2025, with $3.2 billion related to the Epidiolex intangible asset and $0.9 billion related to the Vyxeos intangible asset [565]. Foreign Exchange and Risk Management - The company has significant operations in Europe and the U.S., exposing it to foreign currency exchange risk as financial statements of foreign subsidiaries are translated to U.S. dollars [578]. - A hypothetical 10% strengthening or weakening in exchange rates for sterling and euro would impact net income by $63.7 million and $6.9 million, respectively [579]. - As of December 31, 2025, the company held foreign exchange forward contracts with notional amounts totaling $575.9 million [580]. - The net asset fair value of outstanding foreign exchange forward contracts was $2.5 million as of December 31, 2025 [580]. - A hypothetical 10% adverse fluctuation in exchange rates would decrease the fair value of foreign exchange forward contracts by $21.1 million [580]. - The company has entered into foreign exchange forward contracts to manage currency risk, primarily related to sterling and euro denominated net monetary liabilities [580].

news release GODADDY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS Company continues its track record of profitable growth, strong cash generation Announces integration of GoDaddy's Agent Name Service with MuleSoft, a Salesforce Company TEMPE, Ariz., February 24, 2026 /PRNewswire/ - GoDaddy Inc. (NYSE: GDDY) today reported financial results for the fourth quarter and full year that ended December 31, 2025. "GoDaddy demonstrated strong performance in 2025, and we are leveraging our domain leadership, glo ...

Exhibit 99.1 Universal Reports Fourth Quarter 2025 Results * Reconciliations of GAAP to non-GAAP financial measures are provided in the attached tables. Fort Lauderdale, Fla., February 24, 2026 – Universal Insurance Holdings (NYSE: UVE) ("Universal" or the "Company") reported fourth quarter and full year 2025 results. "We had an outstanding quarter and I am proud of the progress we have made in 2025," said Stephen J. Donaghy, Chief Executive Officer. "We're continuing to see the benefits of Florida's legisl ...

—New Products Accounted for 24% of Full Year Sales, Up From 18% the Prior; Double-Digit Growth in Railing Sales— —Meaningful Increase in Home Center Stocking Locations Heading Into 2026— Exhibit 99.1 NEWS RELEASE TREX COMPANY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS —Higher-Than-Expected Fourth Quarter Sales Capped a Year of Resilient Performance— —Repurchased $50 Million of Trex Common Stock in Q4; Board Authorizes $150 Million share buyback authorization for 1H 2026— —2026 Guidance Anticipates Re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 814-00754 SLR INVESTMENT CORP. (Exact name of registrant as specified in its charter) (State of Incorporation) (I.R.S. Employer 5 ...

Exhibit 99.1 Navitas Semiconductor Announces Fourth Quarter and Full Year 2025 Financial Results TORRANCE, Calif., Feb. 24, 2026 – Navitas Semiconductor, (Nasdaq: NVTS), an industry leader in next- generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, today announced unaudited financial results for its fourth quarter and full year 2025 ended December 31, 2025. "We closed out the year with a productive fourth quarter, as we continued to accelerate our pivot to Nav ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 or Revvity, Inc. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ________ Commission file number 001-5075 _____________________________________ 77 4th ...

| Table of Contents: | Page: | | --- | --- | | Production Volumes by Asset Area | 2 | | Production and Pricing | 4 | | Consolidated Statements of Income | 6 | | Consolidated Balance Sheets | 8 | | Consolidated Statement of Cash Flows | 10 | | 2026E Guidance | 12 | | Derivatives | 13 | | Non-GAAP Reconciliations | 14 | | Definitions | 15 | | Adjusted Net Income | 16 | | Adjusted EBITDA | 18 | | Adjusted Free Cash Flow | 20 | | Recurring General and Administrative Expenses | 22 | Page 1 Production Volumes by ...

EXHIBIT 99.1 Net income was $24.3 million in the fourth quarter, or $0.20 diluted net income per common share, compared to net income of $30.7 million, or $0.26 diluted net income per common share, in the fourth quarter of 2024. For the full year, net income was $99.7 million, or $0.82 diluted net income per common share, compared to net income of $141.2 million, or $1.23 diluted net income per common share, in 2024. Cash and investments were $532.4 million at December 31, 2025, compared to $603.2 million a ...